Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) CEO Anthony Tennyson spoke with Proactive's Stephen Gunnion about the company's £1.3 million fundraising and how proceeds will support its CNS pipeline, spanning SVN-001, SVN-002 and SVN-015.
Tennyson said the funding will let Solvonis assess adding international sites to the Phase 3 programme for SVN-001, its severe alcohol use disorder treatment being trialled within the UK's NHS. Including EU sites and data could improve prospects for a European launch or make the programme more attractive to partners.
On SVN-002, developed for moderate to severe alcohol use disorder in the US, the company is repurposing esketamine as an oral thin film via the FDA's 505(b)(2) pathway, building a scientific bridge to Johnson & Johnson (NYSE:JNJ)'s Spravato. Discussions with the FDA continue, with Tennyson saying next steps will "hopefully" involve a small toxicology package ahead of a Phase 2 or possible Phase 2b trial.
The interview also covered SVN-015, Solvonis' proprietary compound targeting methamphetamine and cocaine addiction, with the US National Institute on Drug Abuse now funding further preclinical work following positive initial screening data.
On wider industry interest, Tennyson said: "There are strong tailwinds for the CNS, psychedelics and psychedelic-adjacent industry."
Visit Proactive’s YouTube channel for more interviews and market updates. Give the video a like, subscribe to the channel and enable notifications for future content.
Read Proactive's Editorial Policy here.
#SolvonisTherapeutics #SVN001 #SVN002 #SVN015 #CNS #Biotech #Pharmaceuticals #DrugDevelopment #AlcoholUseDisorder #AddictionTreatment #Neuropsychiatry #ClinicalTrials #Phase3 #FDA #NIDA #BiotechInvesting #LifeSciences #ProactiveInvestors